Delve Bio is a technology company.
Delve Bio has raised $35.0M across 1 funding round.
Delve Bio has raised $35.0M in total across 1 funding round.
Delve Bio has raised $35.0M in total across 1 funding round.
Delve Bio's investors include Perceptive Advisors.
Delve Bio is a biotechnology company developing precision diagnostics for infectious diseases through metagenomic next-generation sequencing (mNGS) technology.[1][2][3] Its flagship product, Delve Detect, performs comprehensive pathogen detection—including bacteria, fungi, parasites, and viruses—with a single test and 48-hour turnaround, analyzed via the proprietary Delve Decide bioinformatics pipeline, serving labs, clinicians, and hospitals to diagnose routine and rare infections.[1][3][4][6] This addresses the limitations of traditional "guess and test" methods that rely on targeted panels, reducing prolonged hospital stays and inappropriate treatments while enabling faster, hypothesis-free identification.[2][3] Founded in 2022 and headquartered in San Francisco, the company has raised $35M in Series A funding from investors like Google Ventures (GV), Section 32, and Perceptive Xontogeny Venture Fund II, showing strong early momentum with recent data on viral subtyping presented in May 2025.[1][3][4]
Delve Bio was founded in 2022 by renowned experts in genomics and infectious diseases: Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, who brought decades of pioneering research from institutions like UCSF.[1][3][4] The idea emerged from their work translating lab-based mNGS—initially developed for research—into clinical tools, highlighted by pivotal moments like Joe DeRisi's 2016 TEDMED talk on next-gen sequencing for mysterious infections, New York Times coverage as "The Disease Detective," and research by DeRisi and Wilson on treating rare brain-eating amoeba infections.[2] Brad Murray serves as co-founder and CEO, driving commercialization to bring this "game-changing" technology from academia to clinics, backed by exclusive UCSF licensing and top investors.[3][4][5]
Delve Bio stands out in infectious disease diagnostics through these key strengths:
Delve Bio rides the genomics revolution in diagnostics, extending oncology and rare disease successes to infectious diseases long overlooked despite their global burden.[3][5] Timing is ideal post-pandemic, as rising antimicrobial resistance, complex infections, and demands for rapid, comprehensive testing amplify mNGS's value amid market forces like hospital efficiency pressures and pathogen unpredictability.[2][3][4] By commercializing UCSF-honed tech, it influences the ecosystem—partnering with leading institutions, attracting elite VC (e.g., GV), and setting standards for "test once and know," potentially shortening diagnostics from weeks to days and curbing outbreaks.[1][2][4]
Delve Bio is poised to make mNGS the standard for infectious disease testing, with expansion into more viral subtyping, broader hospital adoption, and platform enhancements driving growth beyond its $35M Series A.[1][4] Trends like AI-augmented bioinformatics, personalized medicine, and global health threats will accelerate its trajectory, evolving its influence from niche diagnostics to ecosystem-wide impact—echoing how its founders' research already saved lives from rare pathogens.[2][3] As precision medicine scales, Delve could redefine "what's next" for clinicians facing the unknown, minimizing humanity's pathogen toll.[2][4]
Delve Bio has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $35.0M Series A | Perceptive Advisors |